Cargando…

Sodium-glucose Cotransporter 2 Inhibitor Use: A Pharmaco-ergonomic Qualification Tool

Pharmaco-ergonomics implies tailoring the drug therapy to an individual patient's requirement(s). The development of sodium-glucose cotransporter 2 inhibitor (SGLT2-i) agents has impelled multiple clinical considerations, in the management of type-2 diabetes. This paper attempts to summarize th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalra, Sanjay, Unnikrishnan, A. G., Baruah, Manash, Kawatra, Pallavi, Ved, Jignesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628551/ https://www.ncbi.nlm.nih.gov/pubmed/28989889 http://dx.doi.org/10.4103/ijem.IJEM_184_17

Ejemplares similares

Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
por: Kalra, Sanjay, et al.
Publicado: (2016)

Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes – Results from a Retrospective Single-centre Study
por: Baruah, Manash P, et al.
Publicado: (2019)

Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update
por: Kalra, Sanjay, et al.
Publicado: (2020)

Medication counselling with sodium glucose transporter 2 inhibitor therapy
por: Kalra, Sanjay, et al.
Publicado: (2014)

Diabetes Destiny in our Hands: Achieving Metabolic Karma
por: Kalra, Sanjay, et al.
Publicado: (2017)

Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet?
por: Kalra, Sanjay, et al.
Publicado: (2018)

Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus
por: Unnikrishnan, A. G., et al.
Publicado: (2018)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay
Publicado: (2016)

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2018)

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
por: Kalra, Sanjay, et al.
Publicado: (2015)

The other insulin story of 1921
por: Unnikrishnan, Ambika Gopalakrishnan, et al.
Publicado: (2011)

Thyromimetics: What does the future hold?
por: Unnikrishnan, A. G., et al.
Publicado: (2012)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
por: Jahangiri, Soodeh, et al.
Publicado: (2023)

Celebrating life with Rita Levi-Montalcini: A hundred years and more
por: Kalra, Sanjay, et al.
Publicado: (2012)

Endocrine hypertension: Changing paradigm in the new millennium
por: Baruah, Manash P., et al.
Publicado: (2011)

Hypothyroidism in pregnancy: From unanswered questions to questionable answers
por: Kalra, Sanjay, et al.
Publicado: (2013)

Diabetes therapy by the ear
por: Kalra, Sanjay, et al.
Publicado: (2013)

Interaction, Information, Involvement (The 3I strategy): Rebuilding Trust in the Medical Profession
por: Kalra, Sanjay, et al.
Publicado: (2017)

Responsible Patient-centered Care
por: Kalra, Sanjay, et al.
Publicado: (2017)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Publication trends in the Indian Journal of Endocrinology and Metabolism
por: Kalra, Sanjay, et al.
Publicado: (2011)

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control
por: Baruah, Manash Pratim, et al.
Publicado: (2019)

A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors
por: Chaurasia, Pallavi Prakash, et al.
Publicado: (2021)

Metabolic Karma in Diabetes Care: Medico-philosophical Reflections
por: Kalra, Sanjay, et al.
Publicado: (2017)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

Sodium–glucose cotransporter-2 inhibitors in patients without diabetes
por: Fryml, Elise, et al.
Publicado: (2023)

Pentads and Hexads in Diabetes Care: Numbers as Targets; Numbers as Tools
por: Kalra, Sanjay, et al.
Publicado: (2017)

Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Heyman, Samuel N., et al.
Publicado: (2017)

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
por: Wan, Ningning, et al.
Publicado: (2018)

Sarcopenia, frailty circle and treatment with sodium–glucose cotransporter 2 inhibitors
por: Sasaki, Takashi
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_917b7mq27ubu1bf3j4km3695kk